The value of immunoprophylaxis for cytomegalovirus infection with intravenous immunoglobulin in pediatric liver transplant recipients receiving a low-dose immunosupressive regimen

Pediatric Transplantation

Volumn 14, Issue 1, 2010, Pages 67-71

  Krampe, Katrin ^a   Briem Richter, Andrea ^a   Fischer, Lutz ^a   Nashan, Bjoern ^a   Ganschow, Rainer ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Children; Cytomegalovirus; Immunosuppression; Intravenous immunoglobulins; Liver transplantation

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; GANCICLOVIR; HUMAN IMMUNOGLOBULIN; METHYLPREDNISOLONE; PREDNISOLONE;

ACUTE GRAFT REJECTION; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT SURVIVAL; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INFECTION RISK; LIVER TRANSPLANTATION; LOW DRUG DOSE; MALE; PATIENT MONITORING;

CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INFANT; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 74349125848     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2008.01120.x     Document Type: Article

References (17)

1. Bowman J, Green M, Scnatlebury V, et al. OKT3 and viral disease in pediatric liver transplant recipients. Clin Transplant 1991 : 5 : 294 300.
2. Gane E, Saliba F, Valdecasea G, et al. Randomised trial of efficiacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver transplant recipients. Lancet 1997 : 350 : 1729 1733.
3. Campbell AL, Herold BC. Strategies for the prevention of cytomegalovirus infection and disease in pediatric liver transplantation recipients. Pediatr Transplant 2004 : 8 : 619 627.
4. Green M. Viral infections and pediatric liver transplantation. Pediatr Transplant 2002 : 6 : 20 24.
5. Schiff RI. Intravenous gammaglobulin: Pharmacology, clinical use and mechansim of action. Pediatr Allergy Immunol 1994 : 5 : 127 156.
6. Pescovitz MD. Antiviral therapies for cytomegalovirus in solid-organ transplantation. Transplantation 2007 : 84 : S2 S6.
7. Sester U, Gaertner BC, Wilkens H, et al. Difference in CMV-specific t-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant 2005 : 5 : 1483 1489.
8. Demetris AJ, Batts KP, Dhillon AP, et al. Banff schema for grading liver allograft rejection: An international consensus document. Hepatology 1997 : 25 : 658 663.
9. Gerna G, Baldanti F, Lilleri D, et al. Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: A prospective, randomized, controlled, open-label trial. Transplantation 2003 : 75 : 1012 1019. (Pubitemid 36438531)
10. Strippoli GFM, Hodson EM, Jones C, Craig JC. Pre-emptive treatment for cytomegalovirus disease in solid organ transplant recipients. Transplantation 2006 : 81 : 139 145.
11. Snydman DR, Werner BG, Dougherty NN, et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1993 : 119 : 984 991.
12. Preiksaitis JK, Brennan D, Fishman J, Allen U. Canadian Society of Transplantation Consensus Workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005 : 5 : 218 227.
13. Infectious Diseases Community of Practice, American Society of Transplantation. Guidelines for the prevention and management of infectious complications of solid organ transplantation: Cytomegalovirus. Am J Transplant 2004 : 4 (Suppl. 10 51 58.
14. Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: A meta-analysis. Clin Transplant 2008 : 22 : 89 97.
15. Razonable RR, Van Cruijsen H, Brown RA, et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J Infect Dis 2003 : 187 : 1801 1808.
16. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000 : 355 : 2032 2036.
17. Renoult E, Clermont MJ, Phan V, et al. Prevention of CMV disease in pediatric kidney transplant recipients: Evaluation of pp67 NASBA-based pre-emptive ganciclovir therapy combined with CMV hyperimmune globulin prophylaxis in high-risk patients. Pediatr Transplant 2008 : 12 : 420 425.